ライフサイエンスコーパス: anticancer drug

1 resence of chlorambucil as a model template (anticancer drug).

2 nificantly improves the effectiveness of the anticancer drug.

3 gamation of two characteristics of a perfect anticancer drug.

4 engitide will not be further developed as an anticancer drug.

5 n of the therapeutic responses of a specific anticancer drug.

6 i warrants further evaluation as a potential anticancer drug.

7 a promising lead for the development of new anticancer drugs.

8 tive target for the development of effective anticancer drugs.

9 icacy of clinically important Top2-targeting anticancer drugs.

10 ts to create the next generation of platinum anticancer drugs.

11 or development of efficient antimalarial and anticancer drugs.

12 ug loadings and co-delivery of two different anticancer drugs.

13 increasing the efficacy of a broad range of anticancer drugs.

14 st cancer cells as well as their response to anticancer drugs.

15 op2 engagement of DNA damage or poisoning by anticancer drugs.

16 ad for developing a new mechanistic class of anticancer drugs.

17 me and ultimately could impact the design of anticancer drugs.

18 or inevitably acquire such when treated with anticancer drugs.

19 sight into the future design of Ti(IV)-based anticancer drugs.

20 Fluoropyrimidines are frequently prescribed anticancer drugs.

21 ects significantly limit the applications of anticancer drugs.

22 l lines showed synergic effect with selected anticancer drugs.

23 esents a novel target for the development of anticancer drugs.

24 d numerous TFs whose activity interacts with anticancer drugs.

25 re found to become resistant against various anticancer drugs.

26 ncer treatment and a useful adjunct of other anticancer drugs.

27 of rapamycin and its analogues as candidate anticancer drugs.

28 g design for NEET Fe-S cluster-destabilizing anticancer drugs.

29 01 was combined with approved small-molecule anticancer drugs.

30 strategy for the design of safe metal-based anticancer drugs.

31 eup of a patient's tumor and its response to anticancer drugs.

32 ueous solution for the efficient delivery of anticancer drugs.

33 urrently being tested clinically as targeted anticancer drugs.

34 rovide insight into the development of novel anticancer drugs.

35 ntly occurring adverse event associated with anticancer drugs.

36 on and is therefore an attractive target for anticancer drugs.

37 ) as a trigger for the controlled release of anticancer drugs.

38 revealed a heterogeneous distribution of all anticancer drugs.

39 to potentiate the efficacy of platinum-based anticancer drugs.

40 t limits the effectiveness of currently used anticancer drugs.

41 are the major sources of currently available anticancer drugs.

42 new analytical methods are needed to measure anticancer drugs.

43 a major contributing factor in resistance to anticancer drugs.

44 nd early phase clinical testing as potential anticancer drugs.

45 ficity and on-demand therapeutic efficacy of anticancer drugs.

46 clinical data showing patient resistance to anticancer drugs.

47 have been reported with these new classes of anticancer drugs.

48 of structurally diverse compounds including anticancer drugs.

49 ve important applications as antibiotics and anticancer drugs.

50 d thus is a common target for antibiotic and anticancer drugs.

51 elopment and may represent novel targets for anticancer drugs.

52 lating compounds that represent the earliest anticancer drugs.

53 large storage space and release channels for anticancer drugs.

54 ibodies, an increasingly successful class of anticancer drugs.

55 ance and serves as a major target of several anticancer drugs.

56 ging evidence in favor of SMAPs as potential anticancer drugs.

57 ic load should make tumors more sensitive to anticancer drugs.

58 es together with their response to 24 common anticancer drugs.

59 ponsible for anticancer activity of platinum anticancer drugs.

60 inum-containing molecules are widely used as anticancer drugs.

61 rating 3D mechanical cues into screening for anticancer drugs.

62 pplications as antimicrobial, antiviral, and anticancer drugs.

63 the development of heparanase inhibitors as anticancer drugs.

64 ce by cancer cells limit the use of platinum anticancer drugs.

65 containing functional properties of various anticancer drugs, a series of compounds were identified

66 ng that paclitaxel and other clinically used anticancer drugs actively induce metastasis even while s

67 To explore distribution of the anticancer drugs afatinib, erlotinib, and sorafenib, a c

68 e been developed that show promise as potent anticancer drugs against various solid and hematological

69 mor multidrug resistance (MDR) is to deliver anticancer drug along with P-glycoprotein (P-gp) inhibit

70 Moreover, camptothecin (CPT) is used as the anticancer drug and modified into a dimer (CPT)2 -ss-Mal

71 specific role for STING as a receptor for an anticancer drug and uncover important insights that may

72 stance calls for continuously developing new anticancer drugs and combination chemotherapy regimens.

73 transporter that confers resistance to many anticancer drugs and plays a role in the disposition and

74 ic analysis could predict the sensitivity to anticancer drugs and the clinical outcome of patients wi

75 mechanisms of action of ruthenium(ii)-based anticancer drugs and the relationship between their chem

76 sistance has emerged for almost all approved anticancer drugs and will most probably emerge for newly

77 ted by coencapsulating doxorubicin (DOX) (an anticancer drug) and IR780 iodide (IR780) (an NIR-absorb

78 Currently there are no curative anticancer drugs, and drug resistance is often acquired

79 roenvironment stress, chemotherapy, targeted anticancer drugs, and even immunotherapy.

80 of rare but serious toxicities caused by new anticancer drugs, and there are costs associated with th

81 xpected proteins bound by diverse compounds (anticancer drugs, antibiotics).

82 We identified anticancer drugs approved by the U.S. Food and Drug Admi

83 Many new anticancer drugs approved over the past decade are "targ

84 targeting, encapsulation, and release of an anticancer drug are demonstrated in vitro with a 40% imp

85 Mutants sensitive to 5-fluorouracil, an anticancer drug are under-represented within the 305 pos

86 inical and clinical development of these new anticancer drugs are also discussed.

87 Newly approved anticancer drugs are associated with increased toxicity,

88 Many antiviral and anticancer drugs are nucleoside analogs that target poly

89 Most of the FDA approved anticancer drugs are organic molecules, while metallodru

90 A compound analysis revealed altretamine, an anticancer drug, as an inhibitor of glutathione peroxida

91 arget of camptothecin and indenoisoquinoline anticancer drugs, as it forms Top1 cleavage complexes (T

92 First, most (perhaps all) anticancer drugs, as well as ionizing radiation, affect

93 the effects of three or more antibiotics or anticancer drugs at all doses based only on measurements

94 together, our data suggests key targets for anticancer drugs based on cellular genotypes and their s

95 ir of DNA damage produced by a redox-cycling anticancer drug, beta-lapachone (beta-lap).

96 icroorganism may be the true producer of the anticancer drug, but its genome has remained elusive due

97 sors are attractive candidates for measuring anticancer drugs, but currently few biosensors can achie

98 TOP2 poisons are valuable and widely used anticancer drugs, but they are associated with the occur

99 ing cancer proteins are sufficient to screen anticancer drugs by an array-based SPRi technique with e

100 n enhancing and site-directing the effect of anticancer drugs by illumination, which initiates locali

101 is work, a biosensor was developed to detect anticancer drugs by modifying carbon paste electrodes wi

102 livery system (DDS) to release two different anticancer drugs (caffeic acid and chlorambucil, 1 equiv

103 odytes nimmoniana is a rich source of potent anticancer drug camptothecin (CPT) whose biosynthetic pa

104 Alterations in renal clearance of anticancer drugs can affect the occurrence of toxicities

105 Activity of IP anticancer drugs can be further potentiated by encapsula

106 was observed that exposure to high doses of anticancer drugs can induce the emergence of a subpopula

107 our findings suggest that 4o is a promising anticancer drug candidate that warrants further preclini

108 Among them, Ru-based anticancer drug candidates have become a central subject

109 ensive mitochondrial scission induced by the anticancer drug cisplatin or oxidative stress.

110 r of TRPV4, GSK1016790A, in combination with anticancer drug cisplatin, significantly reduced tumor g

111 vantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of n

112 ar printing for high-throughput screening of anticancer drug combinations.

113 se of pharmacokinetic approaches to increase anticancer drug concentrations within the solid tumor co

114 Conclusion Anticancer drug costs may change substantially after lau

115 Cisplatin, one of the most widely used anticancer drugs, crosslinks DNA and ultimately induces

116 We found that the binding of candidate anticancer drug, curaxin, to cellular DNA results in unc

117 in the colorimetric assay of the alkylating anticancer drug cyclophosphamide.

118 tumor activity comparable to a commonly used anticancer drug, cyclophosphamide, and may form the basi

119 lso compromised the inhibitory effect of the anticancer drug dasatinib on Src kinase oncogenic potent

120 onitoring of biointeraction occurred between anticancer drug, Daunorubicin (DNR), and DNA.

121 Nanoparticle anticancer drug delivery enhances therapeutic efficacies

122 Here we demonstrate the selective anticancer drug delivery into human cells with biocompat

123 A bioinspired cocoon-like anticancer drug delivery system consisting of a deoxyrib

124 The development of anticancer drug delivery systems which retain or enhance

125 y, protected delivery of bioactive moieties, anticancer drug delivery systems, and theranostics (i.e.

126 the surface of CNTs with polymers to produce anticancer drug delivery systems.

127 localize to marrow could improve NP-mediated anticancer drug delivery to sites of bone metastasis, th

128 es knowledge for the development of advanced anticancer drug delivery.

129 g in vitro and potentially also for specific anticancer drug delivery.

130 al cells, it is currently a major target for anticancer drug design.

131 romising strategy for the next generation of anticancer drug development that could be applied to man

132 ding the potential of immunoPET during early anticancer drug development.

133 cy disorders but also for basic research and anticancer drug development.

134 ghted this protein as a potential target for anticancer drug development.

135 on as important tools in cancer research and anticancer drug development.

136 ity of the proteasome as a viable target for anticancer drug development.

137 Last, a chemical screen of 89 anticancer drugs discovers that trisomy 12 raises the se

138 comment on the potential of this approach in anticancer drug discovery.

139 ex as a promising target for p53-restorative anticancer drug discovery.

140 the cell cycle and are validated targets for anticancer drug discovery.

141 nism of action makes it an exciting lead for anticancer drug discovery.

142 lls, endorsing their further exploration for anticancer drug discovery.

143 We show that ZIF-8 crystals loaded with the anticancer drug doxorubicin (DOX) are efficient drug del

144 This system consists of GNPs conjugated to anticancer drug doxorubicin (Dox) by a pH-cleavable bond

145 the NCl for enhanced loading capacity of the anticancer drug doxorubicin (DOX).

146 ap the hydrophobic dye Nile Red (NR) and the anticancer drug doxorubicin (DOX).

147 identified that the chemical linkage of the anticancer drug doxorubicin onto squalene, a natural lip

148 ranswell (Twell) support, and exposed to the anticancer drug doxorubicin.

149 The cytotoxic effect of anticancer drugs doxorubicin (DOX), oxaliplatin (OX) as

150 centrations of several analytes-including an anticancer drug (doxorubicin), several TDM-requiring ant

151 e is an attractive target for antibiotic and anticancer drugs due to its essential role in the de nov

152 Anticancer drug efficacy has been tested on circulating

153 used to make cancer cells less resistant to anticancer drugs, especially in HCV-positive HCC patient

154 (III) complexes are promising candidates for anticancer drugs, especially the clinically studied inda

155 tructures of the antibacterial QPT-1 and the anticancer drug etoposide with Staphylococcus aureus DNA

156 Anticancer drugs (etoposide, doxorubicin, and mitoxantro

157 ed to continuously monitor the effect of the anticancer drug fluorouracil (5-FU) on HCT116 cancer sph

158 Cisplatin is the most commonly used anticancer drug for the treatment of testicular germ cel

159 mplexes are promising as a new generation of anticancer drugs for effective oxidant therapy.

160 tic variants direct the choice of 'targeted' anticancer drugs for individual patients.

161 Anthracyclines are effective genotoxic anticancer drugs for treating human malignancies; howeve

162 ophobic and amphipathic compounds, including anticancer drugs from cells.

163 When given the anticancer drug gefitinib or the retroviral drug atazana

164 ar metabolism and cytostatic activity of the anticancer drug gemcitabine (2',2'-difluoro-2'-deoxycyti

165 sor has been tested for immobilization of an anticancer drug gemcitabine (2',2'-difluoro-2'-deoxycyti

166 Our previous study showed that the anticancer drug Gleevec lowers Abeta levels through indi

167 Consequently anticancer drugs have been developed that target this pa

168 s cytokines have been evaluated as potential anticancer drugs; however, most cytokine trials have sho

169 Platinum complexes are the most widely used anticancer drugs; however, new generations of agents are

170 plicated in the development of resistance to anticancer drugs; however, the role and mechanism underl

171 elson (Abl) kinase inhibitors, including the anticancer drug imatinib, as inhibitors of both SARS-CoV

172 tubule assembly and disassembly include many anticancer drugs in clinical use.

173 ion, and to preclinically evaluate candidate anticancer drugs in living animals.

174 r its ability to enhance the accumulation of anticancer drugs in multidrug resistant (MDR) cancer cel

175 activity comparable to that of the standard anticancer drugs in the cell lines A549, HBL-100, HeLa,

176 us to analyze their relative sensitivity to anticancer drugs in vitro using a chemogram, similar to

177 on, as well as lower sensitivity to TRAIL or anticancer drug-induced apoptosis and greater clonogenic

178 ses the sensitivity of human cancer cells to anticancer drug-induced apoptosis.

179 Cell adhesion counteracted anticancer drug-induced hypermethylation of H3K27 via in

180 new therapeutic strategy to protect against anticancer drug-induced peripheral neurotoxicity.

181 metabolites are widely used as antibiotics, anticancer drugs, insecticides and food additives.

182 ll culture results indicative of synergistic anticancer drug interactions rarely translate clinically

183 veloped algorithm are capable of binding the anticancer drug irinotecan (CPT-11) with micromolar affi

184 uccessfully detected the abundance change of anticancer drug irinotecan and its metabolites inside sp

185 The measurement of anticancer drugs is based on competition between 1-chlor

186 of action (MoA) for new and uncharacterized anticancer drugs is important for optimization of treatm

187 Noscapine is a potential anticancer drug isolated from the opium poppy Papaver so

188 topoisomerase I (Top1) inhibitors and potent anticancer drugs killing cancer cells by producing repli

189 ir poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspec

190 some, has been associated with resistance to anticancer drugs, leading autophagy inhibition to be wid

191 iers encapsulate large amount of hydrophobic anticancer drug like paclitaxel while providing a low co

192 Limiting out-of-pocket costs for expensive anticancer drugs like the IMiDs may improve access to or

193 o papers in Cell exploit C. elegans to infer anticancer drug mechanisms.

194 trial importance as the active moiety of the anticancer drug mipsagargin, currently in clinical trial

195 redicts the sensitivity of cells to the five anticancer drugs most frequently used to treat patients

196 ADCs prepared with the anticancer drug N-phenyl maleimide monomethyl-auristatin

197 The Ru-based anticancer drug NKP-1339 was studied applying XANES (Cl

198 rogress in developing mitochondria-targeting anticancer drugs nonetheless has been slow, owing to the

199 evelopment of Bax agonists as a new class of anticancer drugs offers a strategy for the treatment of

200 ng a 3D microenvironment to study effects of anticancer drugs on specific cancer types is essential.

201 s gene-drug associations or select potential anticancer drugs on the basis of their reported results.

202 Food and Drug Administration (FDA)-approved anticancer drugs or compounds currently in clinical deve

203 cy of nanoparticles as delivery vehicles for anticancer drugs or imaging agents.

204 as single agents, in combination with other anticancer drugs, or with radiotherapy).

205 oids upon treatment with the clinically used anticancer drug oxaliplatin.

206 The anticancer drug paclitaxel (Taxol) exhibits paradoxical

207 nt member of this subfamily, metabolizes the anticancer drug paclitaxel, certain antidiabetic drugs,

208 could potentiate the antitumor effect of the anticancer drug paclitaxel.

209 ggressive CIPN model utilizing the frontline anticancer drug, paclitaxel (PTX).

210 In silico analysis identified 390 novel anticancer drug pairs belonging to 10 drug classes that

211 increased the intracellular accumulation of anticancer drugs, particularly doxorubicin and [(3)H]-pa

212 ynthesized as hybrids of the clinically used anticancer drug pemetrexed (PMX) and our 6-substituted t

213 ncluding antimicrobial and antiviral agents, anticancer drugs, photodynamic therapy agents, radiother

214 nm spherical LbL nanocapsules of low soluble anticancer drugs, polyelectrolyte shell thickness contro

215 ardize new therapeutic immunosuppressive and anticancer drugs protocols.

216 t BAX direct activators are potential future anticancer drugs rather than venoms.

217 prehensive approach to designing combination anticancer drug regimens.

218 DNA-damaging anticancer drugs remain a part of metastatic melanoma th

219 Predicting clinical response to anticancer drugs remains a major challenge in cancer tre

220 Smo inhibitor vismodegib, a clinically used anticancer drug reported to distort smell perception in

221 hnologies as well as the development of many anticancer drugs requires a detailed analysis of DNA/RNA

222 DNA polymerase eta (hPol eta) contributes to anticancer drug resistance by catalyzing the replicative

223 Anticancer drug resistance demands innovative approaches

224 have an important role in the acquisition of anticancer drug resistance in a subset of human malignan

225 resistance, further implicating cMET in the anticancer drug response.

226 are no reliable ex vivo models that predict anticancer drug responses in human tumors accurately.

227 ell proliferation, angiogenesis, and altered anticancer drug responses.

228 and further characterized tumorigenesis and anticancer drug responses.

229 Subgroup analyses of study design, anticancer drug, RT type, embolization type, presence of

230 umor response, adverse events, study design, anticancer drug, RT type, embolization type, presence of

231 apid optical microarray imaging approach for anticancer drug screening at specific cancer protein-pro

232 or deeper understanding of cancer pathology, anticancer drug screening, and cancer treatment developm

233 nducive for the efficient delivery of NO and anticancer drugs, simultaneously.

234 A number of established and investigational anticancer drugs slow the religation step of DNA topoiso

235 this information in chemically modifying an anticancer drug so that it is better transported by and

236 onide conjugates of xenobiotics, such as the anticancer drug sorafenib, can also undergo hepatocyte h

237 Targeted therapies now dominate anticancer drug spending.

238 Third, GIANs provide a platform for loading anticancer drugs such as doxorubicin (DOX) for therapy.

239 Moreover, anti-EGFR-iRGD could improve anticancer drugs, such as doxorubicin (DOX), bevacizumab

240 Immunomodulatory anticancer drugs, such as the anti-programmed death-1 dr

241 of AH-7614 containing features found in many anticancer drugs suggests that a novel close chemical an

242 imprinted nanogels for the detection of the anticancer drug sunitinib were synthesized and character

243 1 and GAK inhibitors, including the approved anticancer drugs sunitinib and erlotinib, could block HC

244 Interactions of the hydrophobic anticancer drug tamoxifen (TAM) with lipid model membran

245 th contactless conductivity detection of the anticancer drug tamoxifen as well as its metabolites.

246 ificant efforts to validate telomerase as an anticancer drug target and to develop effective approach

247 ATR is an attractive new anticancer drug target whose inhibitors have potential a

248 and to establish mitochondria as a potential anticancer drug target, understanding the role of functi

249 human AP endonuclease 1, which is as a valid anticancer drug target.

250 re itself has also attracted attention as an anticancer drug target.

251 ell DNA-damage response and is an attractive anticancer drug target.

252 ng cell division, and as such, it is a broad anticancer drug target.

253 Cancer cell mitochondria are promising anticancer drug targets because they control cell death

254 we reflect on the potential of Orai-STIMs as anticancer drug targets.

255 nd pathological processes, and are important anticancer drug targets.

256 Cisplatin is a major anticancer drug that kills cancer cells by damaging thei

257 man exposure to the antibody figitumumab, an anticancer drug that prevents insulin-like growth factor

258 Anticancer drugs that block Top1 are either well-charact

259 nd a concept for next-generation metal-based anticancer drugs that combat platinum resistance.

260 ) inhibitors (HDACi) are clinically approved anticancer drugs that have important immune-modulatory p

261 tment with sunitinib and erlotinib, approved anticancer drugs that inhibit AAK1 or GAK activity, or w

262 Tyrosine kinase inhibitors (TKIs) are anticancer drugs that may be co-administered with other

263 Indeed, approved anticancer drugs that potently inhibit AAK1 or GAK inhib

264 PK11007 may be a lead for anticancer drugs that target cells with nonfunctional p5

265 osts for a cohort of 24 patented, injectable anticancer drugs that were approved by the US Food and D

266 trast to cisplatin or the progenitor RAPTA-C anticancer drugs, the binuclear agents neither arrest sp

267 emonstrate that both types of Top2-targeting anticancer drugs, the catalytic inhibitor dexrazoxane (I

268 urs after treatment with clinically relevant anticancer drugs, the optical metabolic imaging index of

269 for the development of a brand new class of anticancer drugs; the logical basis of such a strategy w

270 cant advantages compared to more traditional anticancer drug therapies that typically rely on apoptos

271 r cells acquired resistance against multiple anticancer drugs, thus suggesting that ECRG2 mutations a

272 process and its application in delivering an anticancer drug to treat cancer cells are also successfu

273 iodistribution of intravenously administered anticancer drugs to bone.

274 Targeted delivery of anticancer drugs to cancerous tissues shows potential in

275 The direct use of anticancer drugs to create their own nanostructures is a

276 Nanoparticles are used to deliver anticancer drugs to solid tumors.

277 BCB1 and ABCG2 limit the exposure of several anticancer drugs to the brain, leading to suboptimal tre

278 The therapeutic targeting and delivery of anticancer drugs to the mitochondria might improve treat

279 he targeted delivery of poorly water-soluble anticancer drugs to tumour sites.

280 ecosystems, engineered from 109 patients, to anticancer drugs, together with the corresponding clinic

281 and high-resolution complexes of GP with the anticancer drug toremifene and the painkiller ibuprofen.

282 can be used to improve therapeutic index of anticancer drugs used for PC treatment.

283 he feasibility and benefits of delivering an anticancer drug using a carrier-free nanoparticle formul

284 the monoterpenoid indole alkaloid (MIA)-type anticancer drugs vincristine and vinblastine, we identif

285 IDA, anthracycline derivative anticancer drug, was adsorbed on the surface of the QDs

286 Doxorubicin (DOX), a widely used clinical anticancer drug, was conveniently loaded into nanocarrie

287 Using 5 common anticancer drugs, we exemplified detection of differenti

288 Cisplatin is a widely prescribed anticancer drug, which triggers cell death by covalent b

289 target for the development of several useful anticancer drugs, which compromise rapidly dividing cell

290 ses are some of the most successful targeted anticancer drugs widely used for cancer treatment; howev

291 eciation of oocyte response to radiation and anticancer drugs will uncover new targets for the develo

292 Doxorubicin is an effective anticancer drug with known cardiotoxic side effects.

293 acid coated nanocrystals of camptothecin, an anticancer drug with poor aqueous solubility and stabili

294 a general method to monitor various types of anticancer drugs with different structures.

295 hioguanine and dasatinib are three important anticancer drugs with high adverse effects in human body

296 g of research directed to development of new anticancer drugs with novel mechanisms of action.

297 ere, we used this assay to rank 62 different anticancer drugs with respect to their effects on chromo

298 Combination of anticancer drugs with therapeutic microRNA (miRNA) has e

299 Platinum-based drugs are widely used as anticancer drugs, yet their mechanism of action remains

300 acteristics of MCF-7 cell lines treated with anticancer drug ZD6474 to evaluate the cytotoxic effect